Key result
SCN5A mutation linked to ~4.5-fold higher risk of life-threatening arrhythmias in drug-induced Brugada ECG.
Why the study?
Limited real-world data exist regarding the extended prognosis and predictors of life-threatening arrhythmias in patients with drug-induced type 1 Brugada ECG.
Cohort (n=606)
Yes
Effect estimate: HR 4.54
p-value: p=.002
Patients with drug-induced type 1 Brugada ECG have a low long-term risk of life-threatening arrhythmias, which is primarily predicted by the presence of an SCN5A mutation.
No takes yet. Share an insight, caveat, or question.
Low event rates support conservative management for most drug-induced Brugada patients; extends risk stratification data by confirming SCN5A as key predictor.
Russo et al. (2024) conducted a cohort in Drug-induced type 1 Brugada electrocardiographic pattern (n=606). Drug-induced type 1 Brugada ECG was evaluated on Composite of appropriate ICD therapies and sudden cardiac death (HR 4.54, p=.002). In patients with drug-induced type 1 Brugada ECG, the overall rate of life-threatening arrhythmias was 3.1%, with the SCN5A mutation being the only independent predictor (HR 4.54; P=.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: